论文部分内容阅读
目的 :观察巴曲酶治疗急性脑梗死 (ACI)后肾功能不全的疗效。方法 :急性脑梗死后肾功能不全患者80例 ,随机分为治疗组及对照组 ,2组患者除给予常规治疗外 ,治疗组给予巴曲酶 ,剂量为d1 1 0BU ,d3和d5各5BU ,均加入生理氯化钠溶液 2 50mL中静脉滴注。疗程 1 5d后进行疗效评定 ,并对治疗前后凝血酶原时间、纤维蛋白原、血小板粘附率及血脂等生化指标进行对比分析。结果 :经 1个疗程治疗后 ,治疗组基本治愈率 73 .8% ,对照组 34 .2 % ,治疗组基本治愈率明显高于对照组 (P <0 .0 1 )。各项生化指标对比提示巴曲酶的抗凝降纤作用突出。结论 :巴曲酶治疗急性脑梗死后肾功能不全安全有效
Objective: To observe the effect of batroxobin on renal insufficiency after acute cerebral infarction (ACI). Methods: Eighty patients with renal insufficiency after acute cerebral infarction were randomly divided into treatment group and control group. In addition to routine treatment, batroxobin was given to the two groups. The dosage was d110BU, and each of d3 and d5 was 5BU. Physiological sodium chloride solution were added 2 50mL intravenous infusion. After treatment for 15d, the curative effect was evaluated, and the biochemical indexes such as prothrombin time, fibrinogen, platelet adhesion rate and blood lipid were compared before and after treatment. Results: After a course of treatment, the cure rate in the treatment group was 73.8% and that in the control group was 34.2%. The cure rate in the treatment group was significantly higher than that in the control group (P <0.01). Comparison of biochemical indicators suggest that batroxobin anticoagulant fibrinolytic prominent role. Conclusion: Batroxobin is safe and effective in treating renal insufficiency after acute cerebral infarction